Table 3:
Demographics | Overall (N=95) N (% or SD) | Ondansetron (N=46) N (% or SD) | Placebo (N=49) N (% or SD) | P-value |
---|---|---|---|---|
Number of participants by study site (UPenn) | 67 (71%) | 32 (48%); | 35 (52%); | 0.84* |
Sex (Male) | 67 (70.1%) | 34 (49%) | 35 (51%) | 0.79 |
Age (yr) | 51.5 (11.3) | 52.9 (9.8) | 50.1 (12.4) | 0.23 |
Race (White) | 60 (63%) | 28 (47%) | 32 (53%) | 0.65 |
Marital Status1 | 50 (53%) | 19 (41%) | 31 (63%) | 0.03 |
Genotype (% Responsive) | 73 (77%) | 34 (47%) | 39 (53%) | 0.51 |
Employment Status | 0.55 | |||
Full-time | 49 (52%) | 22 (48%) | 27 (55%) | |
Part-time | 14 (15%) | 6 (13%) | 8 (16%) | |
Not Working | 32 (34%) | 18 (39%) | 14 (29%) | |
Years of Education | 15.7 (3.2) | 15.6 (3.5) | 15.8 (3.0) | 0.76 |
Annual Income Level | 0.08 | |||
<$40,000 | 32 (34%) | 18 (40%) | 14 (29%) | |
$40,000 - $79,999 | 17 (18%) | 11 (24%) | 6 (12%) | |
$80,000 - $119,000 | 16 (17%) | 4 (9%) | 12 (24%) | |
≥$120,000 | 29 (31%) | 12 (27%) | 17 (35%) | |
Clinical Measures | ||||
AUDIT | 20.2 (6.4) | 21.2 (6.7) | 19.3 (6.0) | 0.13 |
Height (inches) | 68.0 (3.2) | 67.5 (3.2) | 68.5 (3.2) | 0.09 |
Weight (pounds) | 183.6 (34.9) | 178.6 (35.7) | 188.2 (33.9) | 0.46 |
BMI | 27.8 (4.5) | 27.4 (4.8) | 28.1 (4.3) | 0.62 |
Lifetime Major Depression | 12 (13%) | 5 (11%) | 7 (14%) | 0.62 |
Lifetime Anxiety Disorder | 10 (11%) | 7 (15%) | 3 (6%) | 0.15 |
BDI Score | 5.2 (5.2) | 5.9 (5.5) | 4.7 (4.8) | 0.27 |
Drinks per Drinking Day2 | 6.4 (2.8) | 6.5 (2.8) | 6.4 (2.9) | 0.80 |
Pct. Drinking Days2 | 86.9 (18.5) | 86.3 (20.9) | 87.4 (16.2) | 0.77 |
Pct. Heavy Drinking Days2 | 74.0 (18.3) | 75.8 (25.7) | 87.49 (16.2) | 0.52 |
SIP Score2 | 13.4 (9.4) | 14.3 (10.2) | 12.5 (8.5) | 0.34 |
P-value for the comparison of study site by treatment; the other p-values refer to treatment analysis ignoring site; chi-square test for categorical variables and Kruskal-Wallis test for continuous variables